Abstract: A ground visual question-answering method based on dynamic dual-level visual information fusion includes using a dual-level multiscale network, which is divided into language-guided pixel-level features and region-level features. These two scale branches are combined to predict the final textual answer and ground answer. Furthermore, a question-guided dynamic region-level feature localization network is proposed to locate visual information guided by the question and adaptively assign masks of different sizes to ground answers, thereby enhancing the accuracy of locating and segmenting small targets. Additionally, a cross-modal aggregation module is designed to fuse features from both levels, enhancing the fusion of pixel-level and region-level features to improve the segmentation effect of ground answer masks' edges.

Abstract: A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, especially nasopharyngeal carcinoma. The present disclosure further provides a small molecule inhibitor against nasopharyngeal carcinoma, and/or a pharmaceutical composition comprising same, capable of being used for treating nasopharyngeal carcinoma.

Abstract: The present application provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present application further provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBV infection in a lytic and/or latent phase.